ArticleERJ open research2025
Hospitalisations for bronchiectasis compared to COPD and asthma in the USA.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The importance of symptoms in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Understanding how bronchiectasis hospitalisations differ from those of COPD and asthma could guide clinical practice and improve care. This study aims to compare outcomes of hospitalisations for bronchiectasis exacerbation with those for COPD and asthma exacerbations. Methods: This study used a US all-payer database to evaluate hospitalisations for bronchiectasis, COPD and asthma exacerbations from January 2017 to December 2021. Demographic data, hospital characteristics, comorbidities, costs, length of stay and mortality were analysed. Associations between the SARS-CoV-2 pandemic and hospitalisation incidence and mortality were also assessed. A secondary analysis examined outcomes in bronchiectasis exacerbation with overlapping airway diseases. Results: The bronchiectasis cohort (n=232 825) had a median age of 72 years (IQR: 57-81); 59% were female and 73% were white. Compared to COPD and asthma, hospitalisations for bronchiectasis had longer median stays (5 Conclusions: Hospitalisations for bronchiectasis in the USA are associated with worse outcomes, including higher mortality, costs and length of stay, compared to those for COPD and asthma exacerbations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.